News | June 07, 2022
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Bempedoic Acid administered as a 180-mg dose, is approved by the USFDA and European Union for the treatment of hypercholesterolemia
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Food-tech disruptor prepares to vastly scale dairy-identical, non-animal milk protein production in a pioneering sustainable industrial park in Denmark
Key findings underscore the need for better control of glycemia, blood pressure and lipid parameters to prevent diabetes-related complications
Ideal power boosters to strengthen muscles and keep energised for all kinds of physical activities
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
The survey indicates that 30% of people are still feeling depressed or hopeless on a few days as against GOQii’s last year survey on mental Health where 43% of Indians were depressed
It is only the second generic application approved by the USFDA
Subscribe To Our Newsletter & Stay Updated
